Fast-track the Discovery, Translation & Clinical Development Safe, Efficient & Deliverable Treatments to Patients-in-Need
After an exceptionally successful inaugural launch last year, the 2nd Annual Glioblastoma Drug Development Summit returns this year in an exclusive virtual format.
GBM Drug Development is the only devoted meeting for large pharma, biotech and pioneering academics which guarantees to unite all stakeholders under a mutual and ambitious objective of accelerating the practical discovery, translation, and clinical development of safe, effective and deliverable therapies to treat glioblastoma, an extremely aggressive cancer with a huge medical unmet need.
Confronting specific and applied drug development obstacles with inadequate successful treatments, such as the knowledge of glioblastoma’s mechanisms of resistance and lack of penetration via the blood brain barrier, the 2nd GBM Drug Development Summit will help neuro-oncologists, neurosurgeons and oncology professionals from biopharma effectively translate their drug candidates into human clinical trials, whilst optimizing the clinical development process itself to evade further clinical failures.
Brought direct to your home office with a jam-packed agenda and online virtual networking opportunities, this exclusive virtual summit will delve into the common challenges with developing GBM therapies, whilst striving to advance safe and effective therapeutic breakthroughs to patients in need.
Join us as we unite drug developers and academics on a dedicated virtual platform to tackle unique drug development challenges creating obstacles for effective treatments for GBM patients.
Download the draft agenda to see key topics that will be covered.
Expert Speaker Faculty Includes
Co-Founder, Chief Medical Officer
Chief Executive Officer & Managing Director
Kazia Therapeutics Limited
Associate Professor, Neurosurgery, Oncology & Radiation Oncology & Director, Brain Tumor Immunotherapy
John Hopkins Medical Center
Associate Research Director/Bioscience
Karmanos Cancer Institute
Chief Scientific Officer
Director, Center For Neuro-Oncology
Dana-Farber/Brigham & Women’s Cancer Center
Associate Professor of Therapeutic Radiology
Yale School of Medicine
Hear What Past Attendees Have Said
‘’Dynamic, collaborative, engaged and committed. The respectful speakers,
"The conference carried a great balance
- Northwest Biotherapeutics
"Having a series of industry figures giving
- Dana-Farber Cancer Institute